MedTrace Logo

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

NCT05546476 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2025-05-31

Study results available
· View outcomes & findings →

Summary

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

Conditions

Interventions

DRUG

ponsegromab

Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment

DRUG

Placebo for ponsegromab

Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-21
Primary Completion
2024-03-13
Completion
2025-04-23
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • China
  • Hungary
  • Japan
  • Poland
  • Slovakia
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546476 on ClinicalTrials.gov